Global Age-relatedMacularDegeneration (ARMD) Drugs Market Growth (Status and Outlook) 2023-2028

Report ID: 1290901 | Published Date: Jan 2025 | No. of Page: 102 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2017-2028
        2.1.2 Age-relatedMacularDegeneration (ARMD) Drugs Market Size CAGR by Region 2017 VS 2022 VS 2028
    2.2 Age-relatedMacularDegeneration (ARMD) Drugs Segment by Type
        2.2.1 Anti VEGF Drugs
        2.2.2 Photosensitive Drugs
        2.2.3 Others
    2.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type
        2.3.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size CAGR by Type (2017 VS 2022 VS 2028)
        2.3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2022)
    2.4 Age-relatedMacularDegeneration (ARMD) Drugs Segment by Application
        2.4.1 Exudative ARMD
        2.4.2 Atrophy ARMD
    2.5 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
        2.5.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size CAGR by Application (2017 VS 2022 VS 2028)
        2.5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2022)
3 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Player
    3.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Players
        3.1.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Players (2020-2022)
        3.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Players (2020-2022)
    3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Key Players Head office and Products Offered
    3.3 Market Concentration Rate Analysis
        3.3.1 Competition Landscape Analysis
        3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    3.4 New Products and Potential Entrants
    3.5 Mergers & Acquisitions, Expansion
4 Age-relatedMacularDegeneration (ARMD) Drugs by Regions
    4.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions (2017-2022)
    4.2 Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth (2017-2022)
    4.3 APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth (2017-2022)
    4.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth (2017-2022)
    4.5 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth (2017-2022)
5 Americas
    5.1 Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022)
    5.2 Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
    5.3 Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil
6 APAC
    6.1 APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022)
    6.2 APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
    6.3 APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
    6.4 China
    6.5 Japan
    6.6 Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia
7 Europe
    7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs by Country (2017-2022)
    7.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
    7.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia
8 Middle East & Africa
    8.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs by Region (2017-2022)
    8.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022)
    8.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries
9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends
10 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
    10.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Regions (2023-2028)
        10.1.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Regions (2023-2028)
        10.1.2 Americas Age-relatedMacularDegeneration (ARMD) Drugs Forecast
        10.1.3 APAC Age-relatedMacularDegeneration (ARMD) Drugs Forecast
        10.1.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Forecast
        10.1.5 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Forecast
    10.2 Americas Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Country (2023-2028)
        10.2.1 United States Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.2.2 Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.2.3 Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.2.4 Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
    10.3 APAC Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Region (2023-2028)
        10.3.1 China Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.3.2 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.3.3 Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.3.4 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.3.5 India Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.3.6 Australia Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
    10.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Country (2023-2028)
        10.4.1 Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.4.2 France Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.4.3 UK Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.4.4 Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.4.5 Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
    10.5 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Region (2023-2028)
        10.5.1 Egypt Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.5.2 South Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.5.3 Israel Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.5.4 Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
        10.5.5 GCC Countries Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast
    10.6 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Type (2023-2028)
    10.7 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecast by Application (2023-2028)

11 Key Players Analysis
    11.1 Roche
        11.1.1 Roche Company Information
        11.1.2 Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.1.4 Roche Main Business Overview
        11.1.5 Roche Latest Developments
    11.2 Regeneron Pharmaceuticals
        11.2.1 Regeneron Pharmaceuticals Company Information
        11.2.2 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.2.4 Regeneron Pharmaceuticals Main Business Overview
        11.2.5 Regeneron Pharmaceuticals Latest Developments
    11.3 Bayer
        11.3.1 Bayer Company Information
        11.3.2 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.3.4 Bayer Main Business Overview
        11.3.5 Bayer Latest Developments
    11.4 Santen Oy
        11.4.1 Santen Oy Company Information
        11.4.2 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.4.4 Santen Oy Main Business Overview
        11.4.5 Santen Oy Latest Developments
    11.5 Kanghong Pharmaceuticals
        11.5.1 Kanghong Pharmaceuticals Company Information
        11.5.2 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.5.4 Kanghong Pharmaceuticals Main Business Overview
        11.5.5 Kanghong Pharmaceuticals Latest Developments
    11.6 Novartis
        11.6.1 Novartis Company Information
        11.6.2 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.6.4 Novartis Main Business Overview
        11.6.5 Novartis Latest Developments
    11.7 Eli Lilly and Company
        11.7.1 Eli Lilly and Company Company Information
        11.7.2 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.7.4 Eli Lilly and Company Main Business Overview
        11.7.5 Eli Lilly and Company Latest Developments
    11.8 TRACON Pharmaceuticals
        11.8.1 TRACON Pharmaceuticals Company Information
        11.8.2 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.8.4 TRACON Pharmaceuticals Main Business Overview
        11.8.5 TRACON Pharmaceuticals Latest Developments
    11.9 Pfizer
        11.9.1 Pfizer Company Information
        11.9.2 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.9.4 Pfizer Main Business Overview
        11.9.5 Pfizer Latest Developments
    11.10 GSK
        11.10.1 GSK Company Information
        11.10.2 GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.10.4 GSK Main Business Overview
        11.10.5 GSK Latest Developments
    11.11 BIOCAD
        11.11.1 BIOCAD Company Information
        11.11.2 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
        11.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2020-2022)
        11.11.4 BIOCAD Main Business Overview
        11.11.5 BIOCAD Latest Developments
12 Research Findings and Conclusion

List of Tables
    Table 1. Age-relatedMacularDegeneration (ARMD) Drugs Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
    Table 2. Major Players of Anti VEGF Drugs
    Table 3. Major Players of Photosensitive Drugs
    Table 4. Major Players of Others
    Table 5. Age-relatedMacularDegeneration (ARMD) Drugs Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
    Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & ($ Millions)
    Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2022)
    Table 8. Age-relatedMacularDegeneration (ARMD) Drugs Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
    Table 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & ($ Millions)
    Table 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2022)
    Table 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Players (2020-2022) & ($ Millions)
    Table 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Player (2020-2022)
    Table 13. Age-relatedMacularDegeneration (ARMD) Drugs Key Players Head office and Products Offered
    Table 14. Age-relatedMacularDegeneration (ARMD) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    Table 15. New Products and Potential Entrants
    Table 16. Mergers & Acquisitions, Expansion
    Table 17. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions 2017-2022 & ($ Millions)
    Table 18. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Regions (2017-2022)
    Table 19. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & ($ Millions)
    Table 20. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Country (2017-2022)
    Table 21. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & ($ Millions)
    Table 22. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2022)
    Table 23. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & ($ Millions)
    Table 24. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2022)
    Table 25. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022) & ($ Millions)
    Table 26. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Region (2017-2022)
    Table 27. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & ($ Millions)
    Table 28. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2022)
    Table 29. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & ($ Millions)
    Table 30. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2022)
    Table 31. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (2017-2022) & ($ Millions)
    Table 32. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Country (2017-2022)
    Table 33. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & ($ Millions)
    Table 34. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2022)
    Table 35. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & ($ Millions)
    Table 36. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2022)
    Table 37. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region (2017-2022) & ($ Millions)
    Table 38. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Region (2017-2022)
    Table 39. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2017-2022) & ($ Millions)
    Table 40. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2017-2022)
    Table 41. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2017-2022) & ($ Millions)
    Table 42. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application (2017-2022)
    Table 43. Key Market Drivers & Growth Opportunities of Age-relatedMacularDegeneration (ARMD) Drugs
    Table 44. Key Market Challenges & Risks of Age-relatedMacularDegeneration (ARMD) Drugs
    Table 45. Key Industry Trends of Age-relatedMacularDegeneration (ARMD) Drugs
    Table 46. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Regions (2023-2028) & ($ Millions)
    Table 47. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share Forecast by Regions (2023-2028)
    Table 48. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Type (2023-2028) & ($ Millions)
    Table 49. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share Forecast by Type (2023-2028)
    Table 50. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Application (2023-2028) & ($ Millions)
    Table 51. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share Forecast by Application (2023-2028)
    Table 52. Roche Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 53. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 54. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 55. Roche Main Business
    Table 56. Roche Latest Developments
    Table 57. Regeneron Pharmaceuticals Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 58. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 59. Regeneron Pharmaceuticals Main Business
    Table 60. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 61. Regeneron Pharmaceuticals Latest Developments
    Table 62. Bayer Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 63. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 64. Bayer Main Business
    Table 65. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 66. Bayer Latest Developments
    Table 67. Santen Oy Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 68. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 69. Santen Oy Main Business
    Table 70. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 71. Santen Oy Latest Developments
    Table 72. Kanghong Pharmaceuticals Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 73. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 74. Kanghong Pharmaceuticals Main Business
    Table 75. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 76. Kanghong Pharmaceuticals Latest Developments
    Table 77. Novartis Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 78. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 79. Novartis Main Business
    Table 80. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 81. Novartis Latest Developments
    Table 82. Eli Lilly and Company Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 83. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 84. Eli Lilly and Company Main Business
    Table 85. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 86. Eli Lilly and Company Latest Developments
    Table 87. TRACON Pharmaceuticals Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 88. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 89. TRACON Pharmaceuticals Main Business
    Table 90. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 91. TRACON Pharmaceuticals Latest Developments
    Table 92. Pfizer Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 93. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 94. Pfizer Main Business
    Table 95. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 96. Pfizer Latest Developments
    Table 97. GSK Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 98. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 99. GSK Main Business
    Table 100. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 101. GSK Latest Developments
    Table 102. BIOCAD Details, Company Type, Age-relatedMacularDegeneration (ARMD) Drugs Area Served and Its Competitors
    Table 103. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Offered
    Table 104. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue ($ million), Gross Margin and Market Share (2020-2022)
    Table 105. BIOCAD Main Business
    Table 106. BIOCAD Latest Developments
List of Figures
    Figure 1. Age-relatedMacularDegeneration (ARMD) Drugs Report Years Considered
    Figure 2. Research Objectives
    Figure 3. Research Methodology
    Figure 4. Research Process and Data Source
    Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate 2017-2028 ($ Millions)
    Figure 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type in 2021
    Figure 7. Age-relatedMacularDegeneration (ARMD) Drugs in Exudative ARMD
    Figure 8. Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Exudative ARMD (2017-2022) & ($ Millions)
    Figure 9. Age-relatedMacularDegeneration (ARMD) Drugs in Atrophy ARMD
    Figure 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Atrophy ARMD (2017-2022) & ($ Millions)
    Figure 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application in 2021
    Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Player in 2021
    Figure 13. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Regions (2017-2022)
    Figure 14. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2017-2022 ($ Millions)
    Figure 15. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2017-2022 ($ Millions)
    Figure 16. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2017-2022 ($ Millions)
    Figure 17. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2017-2022 ($ Millions)
    Figure 18. Americas Age-relatedMacularDegeneration (ARMD) Drugs Value Market Share by Country in 2021
    Figure 19. Americas Age-relatedMacularDegeneration (ARMD) Drugs Consumption Market Share by Type in 2021
    Figure 20. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application in 2021
    Figure 21. United States Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 22. Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 23. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 24. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 25. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Region in 2021
    Figure 26. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application in 2021
    Figure 27. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 28. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 29. Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 30. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 31. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 32. Australia Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 33. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Country in 2021
    Figure 34. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type in 2021
    Figure 35. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application in 2021
    Figure 36. Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 37. France Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 38. UK Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 39. Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 40. Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 41. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Region in 2021
    Figure 42. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type in 2021
    Figure 43. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Application in 2021
    Figure 44. Egypt Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 45. South Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 46. Israel Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 47. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 48. GCC Country Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth 2017-2022 ($ Millions)
    Figure 49. Americas Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 50. APAC Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 51. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 52. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 53. United States Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 54. Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 55. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 56. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 57. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 58. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 59. Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 60. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 61. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 62. Australia Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 63. Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 64. France Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 65. UK Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 66. Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 67. Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 68. Spain Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 69. Egypt Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 70. South Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 71. Israel Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 72. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
    Figure 73. GCC Countries Age-relatedMacularDegeneration (ARMD) Drugs Market Size 2023-2028 ($ Millions)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
Global Age-relatedMacularDegeneration Drugs Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Global Age-relatedMacularDegeneration Drugs Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Global Age-relatedMacularDegeneration Drugs Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports